AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21910510
Drug: Fimasartan 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 240 mg (fed state)
Trial: 21910510
Drug: Fimasartan 20-480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 20-480 mg (fasted single doses)
Trial: 21910510
Drug: Fimasartan 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 120 mg (fasted repeated doses)
Trial: 21910510
Drug: Fimasartan 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 360 mg (fasted repeated doses)
Trial: 21910510
Drug: Fimasartan (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan (various doses)
Trial: 21910510
Drug: Fimasartan (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan (240 mg in fed state)
Trial: 16923246
Drug: Low-dose antioxidant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose antioxidant supplementation (nutritional doses)
Trial: 12654439
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose Pd-103
Trial: 12654439
Drug: No instances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No instances of rectal ulceration or fistula reported
Trial: 10600654
Drug: Theophylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (5 mg/kg body weight)
Trial: 3942496
Drug: 12 hours
RxNorm normalized name: PATCH, TRANSDERMAL 12 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 hours of antibiotics
Trial: 3942496
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of antibiotics
Trial: 30177406
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field therapy with 50Hz frequency, low intensity of 20Gauss, combined with Conventional physical therapy Protocol
Trial: 30177406
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy Protocol
Trial: 25534298
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi Chuan exercise sessions (Yang style) twice a week for 12 weeks
Trial: 22893563
Drug: Duloxetine 20
RxNorm normalized name: duloxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 20 mg daily
Trial: 20974993
Drug: Combined treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatments (orange juice and grapefruit juice)
Trial: 14613569
Drug: Efalizumab (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab (weekly subcutaneous administration)
Trial: 9792934
Drug: Continuous high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous high-dose IL-2 infusion combined with CTX-based chemotherapy
Trial: 9792934
Drug: Triple chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple chemotherapy (CTX, etoposide and Ara-C)
Trial: 7924128
Drug: lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril 20 mg daily for 12 weeks
Trial: 7924128
Drug: amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine 10 mg daily for 12 weeks
Trial: 4885025
Drug: sulphamethoxazole-trimethoprim combination
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulphamethoxazole-trimethoprim combination (2:1 and 10:1)
Trial: 4885025
Drug: sulphamethoxazole-trimethoprim combination
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulphamethoxazole-trimethoprim combination (5:1)
Trial: 31930678
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin administration (24 international units)
Trial: 25848890
Drug: Sitting with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitting with Vitamin C (VIT) - 2 vitamin C tablets (1 g and 500 mg) ingested at 30 min and 1 h 30 min, respectively
Trial: 16697850
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (outpatient behavioral therapy)
Trial: 16697850
Drug: Added video
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Added video instructions with standard therapy
Trial: 16697850
Drug: Home uroflowmetry
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home uroflowmetry biofeedback with standard therapy
Trial: 16697850
Drug: Home uroflowmetry
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home uroflowmetry biofeedback with standard therapy (per protocol analysis)
Trial: 14990012
Drug: Regular aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular aspirin use for 30-60 months
Trial: 11376916
Drug: Alcohol (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.6 g/kg ethanol)
Trial: 11376916
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg caffeine, 0.0 g/kg ethanol)
Trial: 11376916
Drug: Caffeine alone
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine alone (0 mg caffeine)
Trial: 9400342
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride (up to 60 mg/d)
Trial: 8480929
Drug: Cefoxitin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (3 doses)
Trial: 8480929
Drug: Ceftizoxime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime (2 doses)
Trial: 3079009
Drug: Iron succinylprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron succinylprotein complex (80 mg of elemental iron daily)
Trial: 3079009
Drug: Iron gluconate
RxNorm normalized name: Iron Gluconate 27mg Tablet
DrugBank: Ferrous gluconate (DB14488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron gluconate complex (125 mg of elemental iron daily)
Trial: 29272211
Drug: omega‐3 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega‐3 (1 g/twice daily)
Trial: 29272211
Drug: cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cranberry juice (200 ml, twice daily)
Trial: 29272211
Drug: cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cranberry juice enriched with omega‐3 (200 ml, containing 1 g omega‐3, twice daily)
Trial: 26182775
Drug: Sub-fascial local
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-fascial local anaesthetic (LA) inguinal field block with 20 ml 0.5% bupivacaine, 20 ml 2% lignocaine with adrenaline, 20 ml normal saline, 3 ml NaHCO3
Trial: 19160857
Drug: Intratympanic prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic prednisolone injection
Trial: 19160857
Drug: Carbamazepine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (oral administration)
Trial: 11372003
Drug: 1 mg/mL
RxNorm normalized name: urea 1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/mL aspartame
Trial: 11372003
Drug: 2 mg/mL
RxNorm normalized name: urea 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/mL aspartame
Trial: 11372003
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg aspartame (in vivo)
Trial: 9181653
Drug: Albendazole continuous
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole continuous therapy for 6 months
Trial: 9181653
Drug: Albendazole discontinuous
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole discontinuous therapy for 6 courses of 4 weeks with a 2 week drug-free interval
Trial: 3327669
Drug: Pirprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirprofen (400 mg, b.i.d.)
Trial: 3327669
Drug: Naproxen (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (250 mg, b.i.d.)
Trial: 31622777
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion at 1.5pmol/kg/min
Trial: 31622777
Drug: GIP +
RxNorm normalized name: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIP + GIP(3‐30)NH2 infusion
Trial: 31622777
Drug: GIP(3‐30)NH2 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP(3‐30)NH2 infusion
Trial: 20957469
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (group 2)
Trial: 15498060
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL sub-Tenon's anaesthetic (0.5% bupivacaine/2% lidocaine in a 50:50 mixture)
Trial: 15498060
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL sub-Tenon's anaesthetic (0.5% bupivacaine/2% lidocaine in a 50:50 mixture)
Trial: 8200219
Drug: 250 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 micrograms levonorgestrel in combination with 50 micrograms ethinylestradiol
Trial: 8200219
Drug: 250 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 micrograms norgestimate in combination with 35 micrograms ethinylestradiol
Trial: 3300988
Drug: Cefatrizine once
RxNorm normalized name: cefatrizine
DrugBank: Cefatrizine (DB13266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefatrizine once daily (75 mg/kg/day)
Trial: 3300988
Drug: Cefatrizine twice
RxNorm normalized name: cefatrizine
DrugBank: Cefatrizine (DB13266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefatrizine twice daily (75 mg/kg/day)
Trial: 3300988
Drug: Erythromycin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (50 mg/kg/day in three divided doses)
Trial: 30203327
Drug: Antidepressant monotherapies
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant monotherapies and combinations
Trial: 30203327
Drug: Psychotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy alone or in combination with an antidepressant
Trial: 17100723
Drug: Fluvastatin 40-80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40-80 mg daily
Trial: 12795643
Drug: Insulin‐intensive conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin‐intensive conventional treatment (ICT)
Trial: 12795643
Drug: Insulin‐standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin‐standard treatment (ST)
Trial: 8933299
Drug: Face-to-face prescribing
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face prescribing discussion visits led by a pharmaceutical prescribing adviser (Group 1)
Trial: 8456595
Drug: Oxiracetam (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiracetam (1600 mg/day)
Trial: 3873511
Drug: Ten-day trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten-day trimethoprim-sulfamethoxazole treatment
Trial: 30022331
Drug: Bilateral Dysport®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral Dysport® injections (50+50 units)
Trial: 30022331
Drug: Unilateral Dysport®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral Dysport® injections (100 units)
Trial: 21254871
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg of ethinyl estradiol (EE)/3 mg of drospirenone (DRSP) plus 100 mg of cyproterone acetate (CPA)
Trial: 21254871
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg of EE/3 mg of DRSP plus 100 mg of spironolactone
Trial: 21254871
Drug: 35 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 μg of EE/2 mg of CPA plus 100 mg of CPA
Trial: 18727456
Drug: L‐methionine‐1‐13COOH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐methionine‐1‐13COOH
Trial: 10944138
Drug: Reinduction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinduction therapy before DLI
Trial: 8839865
Drug: VBMCP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBMCP treatment
Trial: 8839865
Drug: VBMCP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBMCP + alternating high doses of cyclophosphamide + prednisone
Trial: 1592959
Drug: No-pill condition
RxNorm normalized name: No Doz Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-pill condition
Trial: 30621562
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab treatment plus ZQMT
Trial: 30621562
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab treatment alone
Trial: 11423507
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG) 8 mg daily
Trial: 11423507
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG) 4 mg daily
Trial: 3314750
Drug: Graded-sequential filling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graded-sequential filling
Trial: 2694799
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg of Madopar HBS
Trial: 25432773
Drug: Odanacatib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib (50 mg once weekly)
Trial: 16690557
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum tablets
Trial: 9260215
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with house dust mite extract (D.pt.)
Trial: 29412458
Drug: Oliceridine (TRV130)
RxNorm normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oliceridine (TRV130) administered in doses ranging from 0.5 to 4 mg every 3-4 hours during the phase 2 study.
Trial: 29412458
Drug: Oliceridine (TRV130)
RxNorm normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oliceridine (TRV130) administered in single doses ranging from 0.15 to 7 mg and multiple doses ranging from 0.4 to 4.5 mg every 4-6 hours during the phase 1 study.
Trial: 27074824
Drug: Finerenone (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone (2.5, 5, 7.5, 10 or 15 mg, up-titrated to 5, 10, 15, 20, or 20 mg, respectively, on day 30)
Trial: 27074824
Drug: Eplerenone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (25 mg every other day, increased to 25 mg o.d. on day 30, and 50 mg on day 60)
Trial: 20826243
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose followed by 75 mg/d) + Aspirin (75 mg/d for first 21 days)
Trial: 20826243
Drug: Aspirin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (75 mg/d) alone
Trial: 19030110
Drug: Absolute Risk
RxNorm normalized name: Honey Absolute
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absolute Risk Reduction, Number Needed to Treat, Event Rates, Tablets Needed to Take, Natural Frequencies
Trial: 12815479
Drug: Control (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (high-dose therapy only)
Trial: 29338824
Drug: Isokinetic eccentric
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isokinetic eccentric training with whey protein isolate supplement (IE + WPI)
Trial: 23601460
Drug: Tobramycin dexamethasone
RxNorm normalized name: dexamethasone / tobramycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin dexamethasone eye ointment
Trial: 23601460
Drug: Tobramycin eye
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin eye ointment (Control)
Trial: 12735660
Drug: Cumulative dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative dose regimen of formoterol (9 + 9 + 18 microg, total 36 microg)
Trial: 12735660
Drug: Single high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high dose of formoterol (36 microg)
Trial: 12735660
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment regimens (cumulative and single high dose)
Trial: 10620003
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (EPA 3.2 g, DHA 2.4 g)
Trial: 8841150
Drug: Arecoline (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline (4 mg/day, n = 6)
Trial: 8841150
Drug: Arecoline (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline (16 mg/day, n = 3)
Trial: 8841150
Drug: Arecoline (optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline (optimal dose for memory enhancement)
Trial: 8841150
Drug: Arecoline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline (0.5 to 40 mg/day during multiple-dose infusions)
Trial: 6435644
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate spray (2 sprays, 2.5 mg)
Trial: 6435644
Drug: Sublingual glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual glyceryl trinitrate (0.3 mg)
Trial: 6435644
Drug: Ordinary isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary isosorbide dinitrate tablet (5 mg)
Trial: 30895698
Drug: Narrow diameter
RxNorm normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow diameter implants (NDIs) (< 3.3 mm)
Trial: 30895698
Drug: Regular diameter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular diameter implants (RDIs) (4.1 mm)
Trial: 30895698
Drug: Narrow diameter
RxNorm normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow diameter implants (NDIs) and Regular diameter implants (RDIs)
Trial: 17123696
Drug: PCOS patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCOS patients without insulin resistance
Trial: 9144613
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol based bisacodyl suppository (PEGBS)
Trial: 9144613
Drug: Conventional bisacodyl
RxNorm normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional bisacodyl suppository based in hydrogenated vegetable oil (HVOBS)
Trial: 7011349
Drug: aminophylline (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aminophylline (0.2 mg kg‐1 min‐1 for 30 min)
Trial: 30144242
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (antimycotic or steroid) and probiotic
Trial: 25438680
Drug: Thiamylal (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamylal (1.5 mg/kg)
Trial: 22909145
Drug: EE 0.03 mg/drospirenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 0.03 mg/drospirenone 3 mg/levomefolate calcium 0.451 mg (SAFYRAL®)
Trial: 22909145
Drug: EE 0.03 mg/drospirenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 0.03 mg/drospirenone 3 mg (Yasmin®)
Trial: 22909145
Drug: levomefolate calcium
RxNorm normalized name: Levomefolate Calcium
DrugBank: Levomefolic acid (DB11256)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: levomefolate calcium 0.451 mg
Trial: 16230721
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin plus oral agents (n = 103)
Trial: 16230721
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin alone (n = 104)
Trial: 16230721
Drug: Oral agent
RxNorm normalized name: DENTAL AND ORAL AGENTS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral agent therapy alone (n = 99)
Trial: 12173326
Drug: Estramustine phosphate
RxNorm normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estramustine phosphate (EMP) as first-line therapy
Trial: 7781349
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (2 g IV)
Trial: 7781349
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (2 g IV) in severe group